Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%.

The counter shed 0.34% to Rs 3,807.60 on the BSE.